Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1437006
This article is part of the Research Topic The Role of Immunotherapy in Urothelial Cancer View all 7 articles

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer

Provisionally accepted
chengbiao Chu chengbiao Chu *Yao Fu Yao Fu *Jun Yang Jun Yang *Xiangshan Fan Xiangshan Fan *Jiong Shi Jiong Shi *
  • Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China

The final, formatted version of the article will be published soon.

    Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a novel immune checkpoint, similar to programmed death-ligand (PD-L1), and has emerged as a potential target for cancer immunotherapy.Until recently, little was known about the expression and role of Siglec-15 in bladder cancer (BC). In this study, we used immunohistochemical staining to assess the expression of Siglec-15 and PD-L1 in 69 primary BC samples and analyzed their relationship with clinicopathologic characters and prognosis.The expression rates of Siglec-15 in the tumor cells, stromal immune cells, and both the tumor and stromal cells were 84.1% (58/69), 50.7% (35/69), and 44.9% (31/69), respectively. The PD-L1 expression rate was 52.2% (36/69), with a positive rate of 17.4% (12/69). PD-L1 expression was inversely correlated with Siglec-15 expression, but the statistical significance was not achieved (P = 0.072). Low stromal Siglec-15 expression was associated with advanced tumor stage (P = 0.010). PD-L1 expression was associated with tumor stage (P = 0.008) and perineural invasion (PNI) (P = 0.048). Kaplan-Meier survival curves showed that stromal Siglec-15 expression was associated with a better prognosis (P = 0.012), although it was not an independent prognostic factor after multivariate analysis (P = 0.236). In summary, this study revealed a high expression rate of Siglec-15 in BC and may provide valuable insights for patient selection in future clinical trials.

    Keywords: Bladder cancer, Siglec-15, PD-L1, Immunohistochemistry, clinicopathologic analyses

    Received: 23 May 2024; Accepted: 29 Nov 2024.

    Copyright: © 2024 Chu, Fu, Yang, Fan and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    chengbiao Chu, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China
    Yao Fu, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China
    Jun Yang, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China
    Xiangshan Fan, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China
    Jiong Shi, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.